Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4980 - NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Immunology;  Translational Research

Tumour Site

Gastric Cancer

Presenters

Valentina Gambardella

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

V. Gambardella1, F. Gimeno-Valiente1, N. Tarazona Llavero2, T. Fleitas Kanonnikoff1, P. Tolosa1, M. Belda Moscardò3, B. Garcia-Mico1, M. Huerta1, S. Roselló2, D. Roda1, A. Cervantes2, J. Castillo2

Author affiliations

  • 1 Medical Oncology, Biomedical Research Institute INCLIVA, 46010 - Valencia/ES
  • 2 Medical Oncology, Hospital Clinico Universitario de Valencia. INCLIVA. CIBERONC Spain, 46010 - Valencia/ES
  • 3 Biobanco Inclivapt 17/0015/0049 B.000768, Biomedical Research Institute INCLIVA, 46010 - Valencia/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4980

Background

Personalized treatment for gastric cancer (GC) represents a big challenge. HER2 is an important driver in 7-34% of cases, playing a relevant role in cell growth and survival. Trastuzumab (T), when combined with chemotherapy, improves survival. No further anti HER2 drugs demonstrated clinical benefit. Resistance to treatment is a serious problem.

Methods

OE 19 and NCI N87, HER2+ GC cell lines, were treated with increasing doses of Lapatinib (L) and T to obtain resistant clones. These were isolated and characterized by performing mutational analysis by Sequenom MassArray and Western blot (WB) to evaluate protein expression. Genome-wide expression profile was conducted. Inhibition of the altered pathways was performed with specific drugs and siRNA to verify if those alterations were responsible for resistance. In vivoexperiment was performed to corroborate the obtained results. A retrospective cohort of HER2 amplified patients treated with T was also analysed. Clinical characteristics and outcomes were collected. An immunohistochemistry (IHC) analysis to evaluate the altered pathway detected in preclinical models was conducted.

Results

L and T resistant clones were obtained. Protein expression underlined the activation of PI3K pathway and of its downstream effector RPS6 protein. Data obtained by microarray were analysed, identifying a large number of genes regulated by NFR2, a transcriptional regulator involved in oxidative stress, detoxification, and drug resistance. NRF2 expression was detected by WB and immunofluorescence. Cells were treated with GSK048 (G), a dual PI3K/TORCH1/2 inhibitor, showing a decrease in cell growth. siRNA of both RPS6 and NRF2 confirmed the decrease of proliferation and when treatment with antiHER2 was administered, sensitivity was restored. Interestingly after inhibiting PI3K pathway NRF2 expression decreases. In xenografts L and G were tested. G reduced both the expression of pRPS6 and NRF2. Patients with high IHC expression of pRPS6 treated with T, experienced worse outcome, suggesting that hyperactivation of the PI3K pathway may make antiHER2 treatment less effective.

Conclusions

Activation of NRF2 via PI3K seems to be consistently related to anti HER2 resistance in HER2 amplified GC.

Clinical trial identification

Legal entity responsible for the study

INCLIVA Biomedical Research Institute.

Funding

INCLIVA Biomedical Research Institute.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.